A New Look at Treating Some Old Mental Disorders

By McCann, Jean | Drug Topics, June 17, 2002 | Go to article overview

A New Look at Treating Some Old Mental Disorders


McCann, Jean, Drug Topics


HEALTH-SYSTEM EDITION

CLINICAL PRACTICE

The American Academy of Pediatrics has now officially classified attention deficit hyperactivity disorder (ADHD) as a chronic disease. Thus, much attention is being paid to treating the condition with drugs that are safe and effective over the long term.

ADHD is but one of several mental disorders increasingly being treated with drugs rather than just talk therapy. New findings about the drug treatments for anxiety, depression, bipolar disorder, schizophrenia, and other less-common mental disorders also occupied psychiatrists as they met recently in Philadelphia for the annual meeting of the American Psychiatric Association (APA). Below are reports on what's new.

For ADHD

This combination of inattention plus hyperactivity and impulsivity is seen in an estimated 3% to 5% of schoolchildren-mostly boys-and in some cases continuing into adulthood. For many years, methylphenidate has been the standard therapy. Now there are new extended-release formulations of the drug that appear to improve compliance, without serious side effects.

Timothy Wilens, M.D., associate professor of psychiatry at Harvard Medical School, studied 240 children aged six through 13 in a multicenter, open-label trial of once-daily extended-release methylphenidate (Concerta, Alza), at doses of 18, 36, or 54 mg. He said he found that the drug did not adversely affect height, weight, or vital signs and did not appear to worsen or induce tics. Concerta is contraindicated in patients with marked anxiety, tension, and agitation because it may aggravate these symptoms. It should not be used in patients with glaucoma, motor tics, or a diagnosis or family history of Tourette's syndrome. It is contraindicated during treatment with monoamine oxidase inhibitors, and it should not be given until at least 14 days after such treatment has been discontinued (hypertensive crises may result). He said these data "clearly demonstrate the safety of once-daily methylphenidate for up to two years."

Two other studies also demonstrated the effectiveness of a new formulation of methylphenidate, dexmethylphenidate HC1 (Focalin, Novartis). One study in 132 patients six to 17 years of age showed that treatment effects could be achieved at half the dose. A second study, in 89 ADHD patients, showed that patients achieved substantial reduction of symptoms over a 44-week period that followed a six-week open-label dose-titration, a doubleblind, placebo-controlled two-week withdrawal period, and then a 44week open-label extension to determine long-term safety and efficacy.

Keith Corners, Ph.D., professor emeritus of psychiatry and behavioral sciences at Duke University Medical Center, said that the results "signify that dexmethylphenidate HCl, which contains only the active d-isomer, is a safe and effective treatment for ADHD at half the dose of methylphenidate."

An open-label, community assessment of a formulation consisting of mixed salts of q and 1-amphetamine, designed to produce a pulse release of the medication Adderall XR (amphetamine and dextroamphetamine, Shire) for pediatric ADHD, produced significant improvement in symptoms after it was switched from other ADHD medications, according to Paul Ambrosini, M.D., of Hahnemann University in Philadelphia.

For anxiety/depression

Generalized anxiety disorder (GAD) afflicts about 2.8% of adults and about 5% of children. An experimental epilepsy drug, pregabalin (Pfizer), was shown to achieve a more rapid and sustained response than alprazolam in a four-week, double-blind, placebo-controlled; trial in 455 patients with moderate to severe GAD.

Mark Pollack, study investigator and director of the anxiety disorders program at Massachusetts General Hospital, said that "pregabalin appears to have a more rapid onset compared with antidepressants." He added that it also appears to have less of a chance of creating physical dependence and to cause less sedation and cognitive impairment than is the case with the benzodiazepines. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • A full archive of books and articles related to this one
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

A New Look at Treating Some Old Mental Disorders
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

    Already a member? Log in now.